It is expected to become the world’s first heavyweight iteration of a major item to be launched on the market
HONG KONG SAR -
Media OutReach Newswire - 7 October 2024 - AIM Vaccine announced on the evening of October 6 that the company has received notification from the National Institutes for Food and Drug Control on the serum antibody test...
Read more: Phase III clinical data of AIM Vaccine iterative serum-free rabies vaccine reaches preset goals